Transcode Therapeutics: Phase 1 TTX-MC138 Clinical Trial Update – Third Cohort Approved and First Cohort Results Revealed!

TransCode Therapeutics Announces Approval for Third Cohort in Phase 1 Clinical Trial Dec. 18, 2024 – Boston, MA TransCode Therapeutics, a leading RNA oncology company, has received approval from the Safety Review Committee (SRC) to advance to the third cohort of patients in its Phase 1 clinical trial. This decision was made following a thorough…

Read More

Discover the Top Cryptocurrencies to Invest in: BlockDAG, DOGE, ETH, ICP, and XLM

Blog Post Article BlockDAG Eyes $30 By 2030, Outshining Doge Uprising, Ethereum Classic, Internet Computer, And Stellar Lumens BlockDAG Network is rapidly approaching a significant milestone in its 9th presale batch, having nearly amassed $20 million. The native BDAG coin, essential for various operations within the BlockDAG ecosystem, is central to this success. In the…

Read More

Discover the Surprising Power of These 3 Unconventional ETFs: Outperforming the S&P 500 in 2023

Navigating the Wide World of Exchange-Traded Funds: A Guide for Casual Investors With thousands of exchange-traded funds (ETFs) available in today’s market, it’s no wonder that the landscape of investing can feel overwhelming for casual investors. However, not to worry – many investors are able to accomplish their financial goals with a relatively small number…

Read More

Virtuals Protocol: Navigating a Downturn in Revenue Amidst Slowing Demand for AI Agents

Virtuals Protocol: A Significant Drop in Daily Trading Revenue The cryptocurrency market has been witnessing a rollercoaster ride in recent times, with various digital assets experiencing significant price fluctuations. Among these, Virtuals Protocol, a decentralized prediction market platform, has seen a drastic decline in its daily trading revenue. According to reliable sources, the platform has…

Read More